'Genomic profiling is shaping personalized cancer treatments'

GENOMIC profiling is now central to therapeutic decision-making in oncology. The clinical management of cancer is undergoing a fundamental shift from organ-based treatment algorithms to biomarker-driven precision strategies. At the heart of this transition is genomic profiling, which is increasingly central to therapeutic decision-making in oncology, said Dr Vamsi Veeramachaneni, chief scientific officer, Strand Life Sciences.

- Nandita Vijayasimha, Bengaluru

Next-generation sequencing (NGS) has become the backbone of precision oncology. Our ability to rapidly profile genetic alterations in cancers has improved both in accuracy and scalability. Platforms that once required extensive infrastructure and multi-week turnaround times are now capable of delivering actionable insights within days, he added.